SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer
Withdrawn before enrolling · Phase 2
Conditions studied: Head and Neck Cancer
In brief
This is a study to investigate the efficacy and safety of ADP-A2M4 in combination with pembrolizumab in HLA-A\*02 eligible and MAGE-A4 positive subjects with recurrent or metastatic Head and Neck cancer.
Key facts
- Study ID
- NCT04408898
- Run by
- Adaptimmune
- People needed
- 0
- Starts
- 2020-07-02
- Expected to finish
- 2021-12-01
- Last updated by the study team
- 2021-11-16
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic Phoenix — Phoenix, Arizona, United States
- University of California San Diego — San Diego, California, United States
- University of Kansas Medical Center — Kansas City, Kansas, United States
- Karmanos Cancer Insitute — Detroit, Michigan, United States
- Providence Cancer Institute Franz Head and Neck Clinic — Portland, Oregon, United States
- Vanderbilt-Ingram Cancer Center — Nashville, Tennessee, United States
- MD Anderson Cancer Center — Houston, Texas, United States
- West Virginia University Cancer Institute — Morgantown, West Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.